Active pharmaceutical ingredients (APIs) and excipients are the two most important components in the production of a medication. API is the raw material, which is used in manufacturing medications, whereas excipient is a substance that functions as a medium to help the body absorb the drug such as lactose or mineral oil in a tablet. Active pharmaceutical ingredients are produced by using highly technological industrial processes, both during the research & development and commercial production phases. Such compounds are developed to provide pharmacological activity or other direct impacts on disease diagnosis, cure, mitigation, therapy, or prevention, or to change the structure and function of the body. The growth of active pharmaceutical ingredient (API) market can be attributed to certain factors such as increasing funding initiatives by the government across different regions. For instance, in May 2020, the U.S. Department of Health and Human Services (HHS) announced that it will provide a funding of US$ 354 million to Phlow Corporation, a pharmaceutical company, under a four-year contract to produce the active pharmaceutical ingredients (APIs) needed for medications to treat patients with COVID-19 and related illnesses.
Market Dynamics
The rising U.S Food & Drug Administration (FDA) approvals for drugs by pharmaceutical companies is further expected to boost the global active pharmaceutical ingredient (API) market growth during the forecast period. For instance, in December 2020, Eily Lilly received the U.S FDA clearance for several medicines including increased dosages of its Trulicity therapy for the treatment of type 2 diabetes, Cyramza for the treatment of metastatic Estimated Glomerular Filteration Rate (EGFR)-mutated non-small cell lung cancer, and tauvid for individuals diagnosed with Alzheimer's disease.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook